REDFILED (Page 3)

PTCT

PTC THERAPEUTICS (PTCT) Closes Sangamo Deal for Fabry Gene Therapy ST-920

PTC Therapeutics has completed its acquisition of ST-920 from Sangamo and expects to finish a rolling BLA submission for accelerated approval in Q4 2026.

Beyers Nel, chief executive officer of Harmony Gold, said the bond offering reflects a disciplined approach to balance sheet

HMY

HARMONY GOLD (HMY) Launches $500M Convertible Bond Offering

Harmony Gold is selling $500 million in guaranteed senior unsecured convertible bonds due 2031 to cut its cost of capital.

Pierre Schurmann is Founder and Chief Executive Officer of Nuvini Group.

NVNI

NUVINI (NVNI) Reports Positive Operating Income, Net Loss Down 76%

Nuvini Group swung to operating income and generated positive cash flow in H1 2026 while narrowing its net loss sharply, though a shareholders' deficit persists.

Moviegoers filled theater seats as box office revenue climbed sharply year over year.

AMC

AMC ENTERTAINMENT Reports Strong August Box Office Gains

AMC posted a 42.2% jump in two-month revenue as North American box office surged 34.8% versus last year.

NUAI

NEW ERA (NUAI) Secures 20-Year Power Deal With Vistra for Texas Site

New Era Energy & Digital locked in a 20-year, up to 207 MW power purchase agreement with Vistra for Phase 1 of its Texas data center project.

SE

SEA (SE) Insider Chen Jingye Sells $6.1M in Shares

Sea Ltd insider Chen Jingye offloaded roughly $6.1 million in Class A shares over two days, cutting his stake by about half.

AXON

AXON Raises $1.15B in 0% Convertible Notes Due 2031

Axon Enterprise sold $1 billion in zero-coupon convertible senior notes, plus a $150 million over-allotment option, to fund capped calls and general corporate uses.

Susan Galbraith leads AstraZeneca's oncology R&D efforts behind the Enhertu breast cancer program.

AZN

ASTRAZENECA'S Enhertu Wins EU CHMP Backing in Early Breast Cancer

CHMP recommended Enhertu for adjuvant use in HER2-positive early breast cancer after Phase III trial cut recurrence risk by 53%.

CagriSema is Novo Nordisk's investigational once-weekly combination therapy for obesity and type 2 diabetes.

NVO

NOVO (NVO) NORDISK's Cagrisema Beats Tirzepatide On Weight Loss In Trial

Phase 3 data show Novo's investigational CagriSema outperformed Eli Lilly's tirzepatide on weight loss in diabetes patients and beat placebo in obesity.

Anthony Eisen, co-founder of Afterpay and a director at Block.

XYZ

BLOCK (XYZ) Director Anthony Eisen Sells $1.4M in Stock Over Three Days

Afterpay co-founder and Block board member Anthony Eisen sold 18,000 Class A shares between 16 and 18 September, still holding about 1.38 million.